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Abstract
miRNAs are the most abundant RNA species to be found in cell-free 
blood, encapsulated within microvesicles or bound to proteins. miR-
NAs play essential roles in the regulation of various biological pro-
cesses. Moreover, speciﬁc changes in miRNA transcription levels or 
miRNA secretory levels have been linked to the development and 
progression of certain age-related diseases. So, they might be an ideal 
target for modulating healthy ageing.
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State of the art
Ageing of the population
The current growth of the world population has major implications 
for humanity: growing poverty and famine, depletion and pollution of 
natural resources essential for human survival and migratory pressure 
from the poor South to the rich North. In absolute terms, the world po-
pulation has reached 7 billion in 2011. According to the United Nations, 
it will exceed 8 billion in 2025 and 9 billion by 2045. To be sustainable, 
the long-term growth rate, i.e. the difference between birth and death 
rates, should not differ much from 0% [Van Bavel, 2013].
Even though the world population will continue to grow in absolute 
ﬁgures for a certain period, the rate of growth in percentages is decrea-
sing, a result of most countries experiencing a demographic transition 
from relatively high to low birth and death rates [Canning, 2011]. The 
decline in mortality and fertility induces the ageing of the population. 
The percentage of people over 60 in the world has risen from 9.2% in 
1990 to 11.7% in 2013 and will be 21% by 2050. It is expected to exceed 
the number of children for the ﬁrst time in 2047. Currently about two-
thirds of them live in developing countries. They will be concentrated 
in less developed regions of the world [Christensen et al., 2009].
The ageing of the population has great social and economic con-
sequences. The number of working-age adults per older person is 
already low in the more developed regions and in some developing 
countries and should continue to decline in the coming decades with 
consequent ﬁscal pressure on support systems for elderly. The incre-
asing mean lifespan of the population is a big success story of huma-
nity, but also poses a challenge that industrialized countries are cur-
rently facing, since ageing is associated with increased susceptibility 
to many diseases like cancer, type 2 diabetes and neurodegenerative 
disorders [Avery et al., 2014]. So it is necessary to fully understand 
the mechanisms of ageing in order to prevent its detrimental aspects.
Discussion
Ageing of the cells
A prominent mechanism strongly linked to cellular ageing is cellu-
lar senescence, i.e. the arrest of irreversible cellular growth of normal 
miRNAs as tools and targets for healthy ageing
29
human cells after serial passages in vitro [Hayflick & Moorhead, 1961]. 
Critically short telomeres, DNA damage, oncogenic signalling or cel-
lular stress can cause this blockage. Senescent cells differ from other 
non-dividing cells, such as quiescent ones, by various markers, and 
morphological changes (however, senescent cells in vivo maintain the 
normal morphology dictated by tissue architecture). It is interesting to 
note that senescent cells are characterized by an irreversible growth 
arrest, altered function / differentiation status, which is reflected by 
an altered intracellular protein expression and secretion proﬁle, called 
senescence associated secretory phenotype (SASP). Biomarkers of se-
nescence include absence of proliferative markers, expression of tumor 
suppressors, cell cycle inhibitors like p21 and/or p16, and often also 
of DNA damage markers as well as senescence-associated β-galactosi-
dase activity due to GLB1 upregulation [Lee et al., 2006], concomitant 
with an increase of the lysosomal content of the senescent cells, which 
allows the lysosomal β-galactosidase to be detected at a suboptimal 
pH (pH 6.0). This probably reflects the increased autophagy occurring 
in the senescent cells together with an enlargement of the lysosomal 
compartment. As previously stated, senescent cells secrete various 
extracellular factors, including transforming growth factor‐β, insulin‐
like growth factor 1‐binding proteins, plasminogen activator inhibitor 
1, and inflammatory cytokines and chemokines that can enhance and 
propagate senescence in autocrine and paracrine mode, as well as tis-
sue remodelling factors. Therefore, senescent cells contribute to the 
well known pro-inflammatory status of ageing [Campisi & d’Adda di 
Fagagna, 2007; Muñoz-Espín & Serrano, 2014].
Several studies over the last ten years have clearly shown that 
senescence has beneﬁcial and harmful effects. In general, transient 
induction of senescence followed by tissue remodelling is advanta-
geous because it contributes to the elimination of damaged cells. In 
contrast, persistent senescence or the inability to eliminate senescent 
cells are harmful. This is particularly relevant in cancer and ageing, 
both characterized by the accumulation of severe cell damage. Ac-
cordingly, senescence is a crucial barrier to cancer progression and 
senescent cells accumulate with ageing. In summary, senescence is a 
response selected to eliminate damaged cells. However, with ageing, 
the complete sequence of senescence-clearance-regeneration is not 
fully accomplished and senescence may become part of the problem 
G. Accardi, C. Caruso, J. Grillari
30
rather than its solution. Thus, senescence is considered an example 
of antagonistic pleiotropy and has been classiﬁed as an antagonistic 
sign of ageing [Muñoz-Espín & Serrano, 2014].
On the other hand, an increasing number of studies have been publi-
shed showing that senescent cells accumulate with age in vivo, contribu-
ting to overall ageing and age-related diseases in an organism. The in-
fluence of senescent cells in ageing has been demonstrated by reactivating 
telomerase in mouse tissues, which subsequently became “rejuvenated”. 
Studies in the models clearly show that the elimination of senescent cells 
delay the ageing process and the onset of age-related diseases. So many 
scientists are looking for substances that can eliminate senescent cells, that 
is, senolytic drugs [Jaskelioff et al., 2011; Weilner et al., 2015a,b].
miRNA and ageing
In recent years, the role of miRNAs in ageing has become increasin-
gly evident. They are small non-coding RNA sequences that regulate gene 
expression through repression of translation. Only recently, however, miR-
NAs have been found to be secreted in systemic and local environments in 
which they are protected from RNAses by either carrying proteins or by 
being packaged into extracellular vesicles (EVs). EVs are vesicles budding 
from cell membranes (ectosomes), are shedded from multivesicular bo-
dies (exosomes) or derive from apoptotic cells (apoptotic bodies) and con-
tain, depending on their origin, proteins, different RNA species including 
mRNAs and miRNAs and/or DNAs. Unlike well-known protein-based 
signalling systems, EVs have the advantage of providing multiple mes-
sages, potentially in a synergistic way. The miRNAs are then taken up by 
recipient cells, modifying the cellular behaviour by the classical miRNA 
induced silencing of target mRNAs (Figure 1) [Hromada et al., 2017].
The origin of circulating miRNAs, however, is in many cases 
unclear, although senescent cells emerge as the possible source of 
such secreted miRNAs. SASP of different types of cells is probably 
reflected into circulating miRNAs [Weilner et al., 2013]. In vitro, se-
nescent cells secrete more EVs per cell than their quiescent control 
cells and the amount of secreted vesicles increases over time after 
induction of stress induced premature senescence. Since differences 
in circulating miRNAs have been found in a variety of age-related di-
seases and the accumulation of senescent cells in the elderly emerges 
as a possible adverse factor in ageing, it is possible to hypothesize 
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Figure 1. The concept of circulating microRNAs. (1) microRNAs are derived 
from intergenic or intronic genomic regions. In case of intergenic miRNAs, the 
initial primary transcripts (not shown) are cleaved by Drosha/Dgcr8 to form 
precursor miRNAs (Pre-miRNA). Alternatively, splicing of intronic miRNAs 
can give rise to pre-miRNAs. (2) Pre-miRNAs are shuttled via Exportin-5 into 
the cytoplasm where cleavage by Dicer into double-stranded miRNA duplexes 
occurs. (3) Single-stranded miRNAs guide the RISC protein complex to target 
mRNAs resulting in translational repression. (4) mature miRNAs as well as 
Pre-miRNAs are sorted into ectosomes, which bud from the cell membrane. (5) 
Intracellularly, multivesicular bodies (MVBs) are formed, which contain exo-
somes of 50–100 nm size. MVBs fuse with the cell membrane to release miRNA 
loaded exosomes from the Donor Cell into the supernatant. (6) Lipoprotein or 
Ago-2 associated miRNAs are present in cell-free liquids. (7) Protein-bound or 
encapsulated miRNAs are transported with the blood stream. (8) Uptake of ex-
tracellular RNA by an Acceptor Cell that is different from the Donor Cell, and 
potentially located in a different tissue. Reproduced from Hackl M, Heilmeier 
U, Weilner S, Grillari J. Circulating microRNAs as novel biomarkers for bone 
diseases - Complex signatures for multifactorial diseases? Mol Cell Endocrinol. 
2016; 432: 83-95 under the terms of the Creative Commons Attribution License.
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that these miRNAs may contribute to a functional decline observed 
during ageing [Dellago et al., 2017]. In senescent mesenchymal bone 
marrow stem cells, the majority of miRNAs are up-regulated, with 
the exception of miR-199b-5p. This is decreased, thus enhancing the 
translation of its target, LAMC1, which encodes laminin proteins ne-
cessary for cell adhesion and migration as well as signal transduction 
[Yoo et al., 2014; Hackl et al., 2016].
In an effort to identify miRNAs commonly regulated during ageing, 
microarray studies were conducted comparing four human replicative 
cell-ageing models and three organismal ageing models. These diverse 
model systems shared a set of commonly down-regulated miRNAs, 
among them members of the miR-17-92 cluster. Several studies using 
different model systems have conﬁrmed the down-regulation of the 
miR-17-92 cluster during ageing, and its up-regulation in centenarians 
considered successful agers [Gombar et al., 2012; Dellago et al., 2017].
On the other hand, in human beings a pilot study analysed 365 cir-
culating miRNA in young, old and centenarians, identifying three gen-
eral models for circulating miRNAs in young, aged, and long-living 
individuals. In particular, the miR-21-5p levels were demonstrated to 
increase in aged, including centenarians. This was replicated in an in-
dependent sample group. Based on the expected involvement of miR-
21-5p with transforming growth factor-ß signalling and its correlation 
with other circulating inflammatory molecules, miR-21-5p was pro-
posed as “ inflamma-miR”, likely linked to the systemic pro-inflamma-
tory status of old people [Olivieri et al., 2012; 2013, Hackl et al., 2016].
In addition to that we recently identiﬁed miRNA signatures as bio-
markers of an important age-related disease: of osteoporosis. From the 
notion, that miR-31 is secreted by senescent endothelial cells in vitro, 
we found that upon EV mediated transfer to mesenchymal stem cells 
block osteogenic differentiation of these recipient cells [Weilner et al., 
2016a]. This prompted us to also test, if other factors from senescent 
cells might have a synergistic effect and indeed found that Galectin-3, 
that seems to be involved in modulating Wnt signalling, is pro-oste-
ogenic, but found at low levels in serum as well as in EVs of elderly 
[Weilner et al., 2016b]. Finally, we set out to identify a signature of miR-
NAs in serum of osteoporotic fracture patients, which by now is based 
on more than 700 individually that were analysed using serum based 
qPCR methods [Heilmer et al., 2016; Kocijan et al., 2016].
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Conclusion
Ageing affects different body tissues and is known to have a ne-
gative impact on the physiology of cells, tissues and organs, resulting 
in reduced functionality and regeneration capacity. Since observation 
in a murine parabiosis models, which, linking the circulation of old 
animals with young animals, may improve the regenerative potential 
of old tissue [Conboy et al., 2005], it was clear that circulating factors 
were important contributors to the ageing phenotype. Consequent-
ly, circulating miRNAs have been carefully studied in the context of 
ageing in recent years [Hackl et al., 2016]. miRNAs are part of the 
SASP, and are transferred by EVs in a paracrine manner. So, they mi-
ght be an ideal target for assessing and modulating healthy ageing, 
especially in the context of osteoporotic fracture risk assessment.
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